JC02 Rec'd PCT/FTT 23 MAY 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/530 499 Filing Date TRANSMITTAL April 6, 2005 First Named Inventor

FORM Page Art Unit Unknown **Examiner Name** Unknown (to be used for all correspondence after initial filing) Attorney Docket Number 100831-1P US Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify **Terminal Disclaimer** Extension of Time Request below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AstraZeneca 4 6 1 Signature Printed name Jianzhong Shen Date Rea. No. May 20, 48,076 200 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or printed name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No : 10/530,499 PCT Application No.: PCT/SE03/01604

Applicant : Pagé et al. PCT Filing Date: October 15, 2003

National Phase Fld (371): April 6, 2005

TC/A.U. : Unknown
Examiner : Unknown

Docket No. : 100831-1P US

Customer No. : 22466

Title : Novel Compounds

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in

an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: May **20**, 2005

Six (Ishtor

Typed or printed name of person signing certificate

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant(s), wish to call the Examiner's attention to and make of record the references cited on the attached forms PTO/SB/08A and SB/08B. Applicants also wish to make the Examiner aware of copending applications: 10/474,549, a PCT national phase filed on April 18, 2002. Copies of the cited references, excluding the U.S. patent, are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A and SB/08B forms.

Appl. No. 10/530,499

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed within three months of the filing date of this application, and before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,

Jianzhong Shen Reg. No. 48,076

302-886-8854

Dated: May 20, 2005

Enclosures: Form PTO/SB/08A

Form PCT/SB/08B References (14)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for Form 1449/PTO 10/530,499 Application Number April 6, 2005 INFORMATION DISCLOSURE Filing Date First Named Inventor Pagé

> **Examiner Name** Attorney Docket No.

Art Unit

Unknown

Unknown

100831-1P US

Considered

STATEMENT BY APPLICANT (Use as many sheets as necessary)

Signature

SHEET 2 of 2

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*						
_		STN International, file CAPLUS, CAPLUS accession no. 1973:87, document no. 78:87, Paglietti G. et al, "Dialkylaminoalkylbenzimidazoles of pharmacological interest", & Studi Sassaresi, Sezione 2: Archivio Bimestrale di Scienze Mediche e Naturali (1971), 49(5-6), 192-203				
		SEKI, T. et al., "2-Benzimidazolethiol derivatives –5-substituted, benzimidazole", Chem. Abstracts, 1969, pg. 445, Vol. 71, No. 13, THE ABSTRACT, No. 61291h, Yakugaku Zasshi, 1969, 89 (5), 617-626				
		PAGLIETTI, G. et al., "Dialkylaminoalkylbenzimidazoles of pharmacological interest III", Chem. Abstracts, 1972, pg. 479, Vol. 77, No. 7, THE ABSTRACT, No. 48338h, Farmaco, Ed. Sci. 1972, 27 (4), 333-342				
		LECOLIER, S. et al., "New benzimidazoles with morphine activity", Chim. Ther., 1967, pgs 16-24, Vol. 2, No. 1	\boxtimes			
		BURKE, T. et al., "Probes for Narcotic Receptor Mediated Phenomena. 7.1 Synthesis and Pharmacological Properties of Irreversible Ligands Specific for μ or δ Opiate Receptors", J. Med. Chem., 1984, pgs. 1570-1574, Vol. 27				
		SMITH, J. et al., "Necklace-Coded Polymer-Supported Combinatorial Synthesis of 2-Arylaminobenzimidazoles", J. Comb. Chem., 1999, pgs. 368-370, Vol. 1				
Examiner	Τ	Date				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in the conformance and not considered. Include copy of this form with next communication to Applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO	Complete if Known		
	Application Number	10/530,499	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Filing Date	April 6, 2005	
	First Named Inventor	Pagé	
	Art Unit	Unknown	
	Examiner Name	Unknown	
SHEET 1 of 2	Attorney Docket No.	100831-1P US	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.1	Document Number Number - Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	i -	US-2,945,044	7-12-1960	Hoffmann et al.	
	Î .	US-			
	·	US-			
		US-			
	1	US-			
	i -	US-			
		US-			
	1	US-			
		⊍S-			
		US-			
		US-			
		US-			
			FOREIGN PATEN	T DOCUMENTS	

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	1	of Patentee or icant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)					T⁵
		WO 97/19063	05-29-1997	Sanofi			
		WO 00/46209	08-10-2000 Sanofi-Synthelabo		Synthelabo		
		WO 02/36590	05-10-2002	Amrad Operations Pty Ltd University of Connecticut AstraZeneca AB AstraZeneca AB Sterling Drug Inc. Serge Lécolier			
		WO 02/060447	08-08-2002				
		WO 02/085866	10-31-2002				
		WO 2004/035548	04-29-2004				
	<u> </u>	EP 0445781	09-11-1991				
	T	FR 1481049	05-19-1967				
Examiner Signature					Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.